Ozvegy-Laczka C - Search Results

1

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, Buday L, Kéri G, Német K, Sarkadi B. Elkind NB, et al. Cancer Res. 2005 Mar 1;65(5):1770-7. doi: 10.1158/0008-5472.CAN-04-3303. Cancer Res. 2005. PMID: 15753373

2

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

Ozvegy-Laczka C, Hegedus T, Várady G, Ujhelly O, Schuetz JD, Váradi A, Kéri G, Orfi L, Német K, Sarkadi B. Ozvegy-Laczka C, et al. Mol Pharmacol. 2004 Jun;65(6):1485-95. doi: 10.1124/mol.65.6.1485. Mol Pharmacol. 2004. PMID: 15155841

3

ABCG2 -- a transporter for all seasons.

Sarkadi B, Ozvegy-Laczka C, Német K, Váradi A. Sarkadi B, et al. FEBS Lett. 2004 Jun 1;567(1):116-20. doi: 10.1016/j.febslet.2004.03.123. FEBS Lett. 2004. PMID: 15165903 Free article. Review.

4

Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization.

Cserepes J, Szentpétery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Váradi A, Sarkadi B, Elkind NB. Cserepes J, et al. Biochem Biophys Res Commun. 2004 Jul 30;320(3):860-7. doi: 10.1016/j.bbrc.2004.06.037. Biochem Biophys Res Commun. 2004. PMID: 15240127

5

Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

Ozvegy-Laczka C, Várady G, Köblös G, Ujhelly O, Cervenak J, Schuetz JD, Sorrentino BP, Koomen GJ, Váradi A, Német K, Sarkadi B. Ozvegy-Laczka C, et al. J Biol Chem. 2005 Feb 11;280(6):4219-27. doi: 10.1074/jbc.M411338200. Epub 2004 Nov 22. J Biol Chem. 2005. PMID: 15557326 Free article.

6

Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.

Ozvegy-Laczka C, Köblös G, Sarkadi B, Váradi A. Ozvegy-Laczka C, et al. Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63. doi: 10.1016/j.bbamem.2004.11.005. Biochim Biophys Acta. 2005. PMID: 15670731 Free article.

7

Single nucleotide polymorphisms modify the transporter activity of ABCG2.

Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE. Morisaki K, et al. Cancer Chemother Pharmacol. 2005 Aug;56(2):161-72. doi: 10.1007/s00280-004-0931-x. Epub 2005 Apr 19. Cancer Chemother Pharmacol. 2005. PMID: 15838659

8

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.

Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Ozvegy-Laczka C, et al. Drug Resist Updat. 2005 Feb-Apr;8(1-2):15-26. doi: 10.1016/j.drup.2005.02.002. Drug Resist Updat. 2005. PMID: 15939339 Review.

9

The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.

Cervenak J, Andrikovics H, Ozvegy-Laczka C, Tordai A, Német K, Váradi A, Sarkadi B. Cervenak J, et al. Cancer Lett. 2006 Mar 8;234(1):62-72. doi: 10.1016/j.canlet.2005.01.061. Epub 2005 Dec 7. Cancer Lett. 2006. PMID: 16337740 Review.

10

Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.

Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, Sarkadi B, Bates SE. Polgar O, et al. Biochemistry. 2006 Apr 25;45(16):5251-60. doi: 10.1021/bi0521590. Biochemistry. 2006. PMID: 16618113 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters